Sulforaphane potentiates the efficacy of chemoradiotherapy in glioblastoma by selectively targeting thioredoxin reductase 1
Cancer Letters · 2025
DOI: 10.1016/j.canlet.2024.217429 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Letters, 2025. Verfasst von Yuqian Ge und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nutrition and Food Hygiene, Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, Jiangsu, 211166, Ch…. Hauptthemen laut MEDLINE: Isothiocyanates, Thioredoxin Reductase 1, Glioblastoma, Sulfoxides. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 60 Literaturangaben.
Abstract (Originalsprache)
Chemoradiotherapy is a conventional treatment modality for patients with glioblastoma (GBM). However, the efficacy of this approach is significantly hindered by the development of therapeutic resistance. The thioredoxin system, which plays a crucial role in maintaining redox homeostasis, confers protection to cancer cells against apoptosis induced by chemoradiotherapy. Herein, we demonstrate that sulforaphane (SFN), an isothiocyanate phytochemical with anti-cancer effects, inhibits the activity of thioredoxin reductase 1 (TrxR1) through covalent conjugation with residues C59/64/497&U498. This inhibition of TrxR1 leads to the accumulation of reactive oxygen species (ROS), thereby enhancing chemoradiotherapy-induced apoptosis in GBM cells. Furthermore, SFN-induced ROS accumulation facilitates the polarization of M1-like macrophages, which synergistically sensitize GBM tumors to chemoradiotherapy. In conclusion, our study unveils that SFN has potential benefits in improving the effect of chemoradiotherapy and prognosis for GBM patients by targeting TrxR1.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nutrition and Food Hygiene, Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, Jiangsu, 211166, China; Institute for Brain Tumors, Jiangsu Key Lab of Cancer Biomarkers,…
- Department of Medicinal Chemistry, School of Pharmacy, Nanjing Medical University, Nanjing, 211166, China.
- Institute for Brain Tumors, Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, Nanjing, Jiangsu, 211166, China;…
- Department of Pharmacology, Guangxi Institute of Chinese Medicine & Pharmaceutical Science, Nanning, 530022, China.
- Department of Neurosurgery, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua, 321000, China.
- Central Laboratory, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua, 321000, China.
Zitieren
APA
Ge, Y., Ge, Z., Tian, F., Tai, X., Chen, D., Sun, S., Shi, Z., Yin, J., Wei, G., Li, D., Wang, L., Xu, W., Tong, M., Liu, F., Zhao, L., Qian, X., & Ge, X. (2025). Sulforaphane potentiates the efficacy of chemoradiotherapy in glioblastoma by selectively targeting thioredoxin reductase 1. Cancer Letters. https://doi.org/10.1016/j.canlet.2024.217429
Vancouver
Ge Y, Ge Z, Tian F, Tai X, Chen D, Sun S, et al. Sulforaphane potentiates the efficacy of chemoradiotherapy in glioblastoma by selectively targeting thioredoxin reductase 1. Cancer Letters. 2025. doi:10.1016/j.canlet.2024.217429
BibTeX
@article{Ge2025,
author = {Ge, Yuqian and Ge, Zehe and Tian, Fuwei and Tai, Xiaoyu and Chen, Dongyin and Sun, Shuhong and Shi, Zhumei and Yin, Jianxing and Wei, Guining and Li, Dongmei and Wang, Lude and Xu, Wenxia and Tong, Minfeng and Liu, Fang and Zhao, Lin and Qian, Xu and Ge, Xin},
title = {Sulforaphane potentiates the efficacy of chemoradiotherapy in glioblastoma by selectively targeting thioredoxin reductase 1},
journal = {Cancer Letters},
year = {2025},
doi = {10.1016/j.canlet.2024.217429}
}
EUVIMED